- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Guard Therapeutics International AB: Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study | 180 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients... ► Artikel lesen | |
| 05.10. | Guard Therapeutics International AB: Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study | 78 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary... ► Artikel lesen | |
| 11.09. | Guard Therapeutics International AB: Guard Therapeutics announces completion of data collection in Phase 2b POINTER study | 634 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery... ► Artikel lesen | |
| 21.08. | Guard Therapeutics International AB: Guard Therapeutics publishes interim report January-June 2025 | 130 | GlobeNewswire (Europe) | The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study - ahead of schedule. The positive final safety review reinforces confidence in the trial... ► Artikel lesen | |
| 05.06. | Guard Therapeutics International AB: Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study | 150 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company's ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 27.05. | Guard Therapeutics International AB: Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study | 188 | GlobeNewswire (Europe) | Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial... ► Artikel lesen | |
| 25.03. | Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study | 352 | GlobeNewswire (Europe) | Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled... ► Artikel lesen | |
| 14.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | 1.751 | Xetra Newsboard | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| 10.03. | Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million | 301 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 27.02. | Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study | 192 | GlobeNewswire (Europe) | Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,06 | -2,96 % | Novonesis (Novozymes A/S): Noma and Novonesis partner to scale deliciousness | ||
| GENMAB | 249,90 | -2,69 % | Genmab A/S: Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. | Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) ("Genmab") announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. ("Purchaser")... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,796 | +1,39 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| VERICEL | 31,000 | -1,27 % | Vericel Corporation: Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 | ||
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia | Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 10,460 | 0,00 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,950 | -2,74 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,394 | -1,50 % | MustGrow Biologics Corp.: MustGrow Announces Grant of RSUs and DSUs | Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors... ► Artikel lesen | |
| REGENXBIO | 11,800 | +5,36 % | REGENXBIO Inc.: REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE Trial of RGX-121 for Treatment of MPS II | 12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II
>80% reduction in CSF levels... ► Artikel lesen | |
| AKEBIA | 2,688 | +3,31 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 | ||
| ZEVRA THERAPEUTICS | 9,000 | -1,10 % | Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call | ||
| FENNEC PHARMACEUTICALS | 7,500 | +1,35 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update | ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | AbbVie wins $56M royalty award from Revance in Botox patent infringement case | ||
| CORVUS PHARMACEUTICALS | 6,760 | +6,96 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis | SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 7,500 | +1,35 % | Cartesian Therapeutics, Inc. - 8-K, Current Report |
GUARD THERAPEUTICS INTERNATIONAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -1,827 (-84,58 %) liegt der Kurs bei 0,333 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.